G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus
G protein–coupled receptors (GPCRs) continue to be important discovery targets for the
treatment of type 2 diabetes mellitus (T2DM). Many GPCRs are directly involved in the …
treatment of type 2 diabetes mellitus (T2DM). Many GPCRs are directly involved in the …
RNAi-based therapeutic strategies for metabolic disease
MP Czech, M Aouadi, GJ Tesz - Nature Reviews Endocrinology, 2011 - nature.com
RNA interference (RNAi) is a robust gene silencing mechanism that degrades mRNAs
complementary to the antisense strands of double-stranded, short interfering RNAs …
complementary to the antisense strands of double-stranded, short interfering RNAs …
Glucagon/GLP-1 receptor co-agonists
J Day, J Patterson, J Chabenne, M Dimarchi… - US Patent …, 2013 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
39690775&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
39690775&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
[HTML][HTML] Prodrugs of NSAIDs: A review
Results: As an outcome the search for a prodrug or mutual prodrug with reduced toxicity has
continued during recent years. This present review emphasizes the common help to revamp …
continued during recent years. This present review emphasizes the common help to revamp …
Calixarene: a versatile material for drug design and applications
The therapy of various diseases by the drugs entrapped in calixarene derivatives is gaining
attraction of researchers nowadays. Calixarenes are macrocyclic nano-baskets which …
attraction of researchers nowadays. Calixarenes are macrocyclic nano-baskets which …
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
RD DiMarchi, DL Smiley, M Dimarchi… - US Patent …, 2013 - Google Patents
Modified glucagon peptides are disclosed having improved solubility and/or half-life while
retaining glucagon agonist activity. The glycogen peptides have been modified by Sub …
retaining glucagon agonist activity. The glycogen peptides have been modified by Sub …
GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
JD Roth, MR Erickson, S Chen… - British journal of …, 2012 - Wiley Online Library
The discoveries of the incretin hormone glucagon‐like peptide‐1 (GLP‐1) and the β‐cell
hormone amylin have translated into hormone‐based therapies for diabetes. Both classes of …
hormone amylin have translated into hormone‐based therapies for diabetes. Both classes of …
Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration
K Antraygues, M Maingot, B Schellhorn… - European Journal of …, 2022 - Elsevier
Acinetobacter baumannii is a gram-negative bacterium causing severe hospital-acquired
infections such as bloodstream infections or pneumonia. Moreover, multidrug resistant A …
infections such as bloodstream infections or pneumonia. Moreover, multidrug resistant A …
Prodrug rewards in medicinal chemistry: an advance and challenges approach for drug designing
This article emphasizes the importance of prodrugs and their diverse spectrum of effects in
the field of developing novel drugs for a variety of biological applications. Prodrugs are …
the field of developing novel drugs for a variety of biological applications. Prodrugs are …
Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
RD DiMarchi, M Dimarchi, J Chabenne - US Patent 8,669,228, 2014 - Google Patents
4,275,152 A 6/1981 Esders et al. 5,359,030 A 10/1994 Ekwuribe(57) ABSTRACT 5,510,459
A 4/1996 Smith et al. 5,512,549 A 4/1996 Chen et a1. Modi? ed glucagon peptides are …
A 4/1996 Smith et al. 5,512,549 A 4/1996 Chen et a1. Modi? ed glucagon peptides are …